Table 2.
Clinical features and management of the 40 identified patients with gout.
| Gout (n = 40) | |
|---|---|
| Years since the first flare, median (IQR) | 15 (10–30) (n = 39) |
| Number of flares, median (IQR) | 3 (1–9) (n = 39) |
| Number of involved joints, median (IQR) | 2 (1–3) (n = 39) |
| Presence of tophi | 3/39 (7.7) |
| Serum urate levels (mg/dl), mean (SD) - at admission - median levels of the previous 5 years |
7.1 (2.6) (n = 24) 6.8 (1.6) (n = 33) |
| Serum urate <6 mg/dl - at admission - median levels of the previous 5 years |
8/24 (33.3) 7/33 (21.2) |
| Urate-lowering agents (ever) | 28/40 (70.0) |
| Urate-lowering agents (current) | 20/40 (50.0) |
| Allopurinol - current use - dose (mg/day), mean (SD) Febuxostat - current use - Febuxostat dose (mg/day), mean (SD) |
16/20 (80.0) 200 (102) 4/20 (20.0) 80 (0) |
| Prophylactic colchicine (ever) | 11/40 (27.5) |
| Prophylactic colchicine (current) | 5/40 (12.5) |
| Use of NSAIDs for gout flares | 25/40 (62.5) |
Data shown as n (%) unless otherwise specified. Number in brackets accounts for complete data. IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs; SD, standard deviation.